Agendia’s tests can identify premenopausal women with low risk of metastasizing to avoid possible overtreatment. In fact, Level 1 evidence shows the majority of women with a MammaPrint UltraLow1 result did not receive chemotherapy, and the distant metastasis free interval was
97% at 5 years.2
Everyone’s breast cancer is unique so having a personalized treatment plan is critical. Watch the videos below to see how we are working to provide tests that help guide customized treatment plans that work for our patients wherever they are on their journey, regardless of menopausal status or age.3
Consistent results you can trust.
PERIOD. OR NO PERIOD.